About Femtogenix
Femtogenix is a company based in London (United Kingdom) founded in 2015. Femtogenix has raised $40.2 million across 2 funding rounds from investors including Research Corporation Technologies. The company has 14 employees as of March 31, 2022. Femtogenix operates in a competitive market with competitors including ArcherDX, Third Wave Technologies, Diagnostic Hybrids, Aptamer Group and Gen-Probe, among others.
- Headquarter London, United Kingdom
- Employees 14 as on 31 Mar, 2022
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Femtogenix Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$3.52 M (USD)0as on Mar 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$40.2 M (USD)
in 2 rounds
-
Latest Funding Round
$36.63 M (USD), Series B
Mar 14, 2022
- Investors
-
Employee Count
14
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Femtogenix
Femtogenix has successfully raised a total of $40.2M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $36.63 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Femtogenix
Femtogenix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research Corporation Technologies is engaged in licensing biomedical technologies.
|
Locked | Locked | Locked |
Investor details for Femtogenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Femtogenix
Investment portfolio details for Femtogenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Femtogenix
Detailed financials for Femtogenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Femtogenix Comparisons
Peer comparison for Femtogenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Femtogenix
Femtogenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Third Wave Technologies, Diagnostic Hybrids, Aptamer Group and Gen-Probe, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Molecular diagnostic devices and reagents are developed and marketed.
|
|
| Locked | Locked | Locked |
Molecular diagnostic kits for infectious diseases are developed and manufactured.
|
|
| Locked | Locked | Locked |
Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development
|
|
| Locked | Locked | Locked |
Provides clinical diagnostics, blood screening, and research products.
|
|
| Locked | Locked | Locked |
Bio-polymer chitosan products are developed for medical uses.
|
Detailed competitors of Femtogenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Femtogenix
Complete news archive for Femtogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Femtogenix
Femtogenix was founded in 2015.
Femtogenix is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Femtogenix is a funded company, having raised a total of $40.2M across 2 funding rounds to date.
As of Mar 31, 2022, the latest employee count at Femtogenix is 14.
Femtogenix, a spin-out company from Kings College London (KCL) is a drug discovery company focussed on developing DNA-interactive payload molecules for use in antibody-drug conjugates (ADCs). Its drug discovery platform claims to enable the design molecules which are capable of binding reversibly andor irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells and when attached to antibodies, these potent cytotoxic agents can be delivered directly to tumors. It is currently looking for a partnership with pharmaceutical companies.
Femtogenix's top competitors include ArcherDX, Aptamer Group and KiOmed Pharma.
Femtogenix has 1 investor. Key investors include Research Corporation Technologies.
The valuation of Femtogenix is $6M as of Sep 2015.